Heparanase
HPSEproteinHeparanase degrades subendothelial heparan sulfate, promoting platelet and leukocyte infiltration and thrombus expansion in STEMI.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleHeparan-sulfate degradation enzyme released by activated cells; thrombus-burden predictor.
Also acts inCoagulation / thrombus
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000173083
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I64
C — confounder / Type-II70
A — assay feasibility72
E — evidence strength28
T1DI (composite)9
Specificity differential (R−C)-6.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2019 · PMID 31215255 · doi